Mersana Therapeutics Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Mersana Therapeutics stock.
View analyst ratings for Mersana Therapeutics or view top-rated stocks.

4 brokers have issued 12-month price targets for Mersana Therapeutics' stock. Their MRSN stock forecasts range from $16.00 to $32.00. On average, they predict Mersana Therapeutics' stock price to reach $21.25 in the next twelve months. This suggests a possible upside of 359.0% from the stock's current price.
View analysts' price targets for Mersana Therapeutics or view top-rated stocks among Wall Street analysts.

Mersana Therapeutics' stock was trading at $6.22 at the beginning of 2022. Since then, MRSN shares have decreased by 25.6% and is now trading at $4.63.
View the best growth stocks for 2022 here.

Mersana Therapeutics saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 5,870,000 shares, an increase of 26.5% from the May 15th total of 4,640,000 shares. Based on an average trading volume of 1,480,000 shares, the short-interest ratio is currently 4.0 days.
View Mersana Therapeutics' Short Interest.

Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for Mersana Therapeutics.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) released its quarterly earnings data on Monday, May, 9th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.28. Mersana Therapeutics had a negative trailing twelve-month return on equity of 119.10% and a negative net margin of 8,826.73%. During the same period last year, the firm earned ($0.50) EPS.
View Mersana Therapeutics' earnings history.

3 employees have rated Mersana Therapeutics CEO Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among Mersana Therapeutics' employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Mersana Therapeutics include ChemoCentryx (CCXI), Ironwood Pharmaceuticals (IRWD), OPKO Health (OPK), Arcus Biosciences (RCUS), Amphastar Pharmaceuticals (AMPH), Xencor (XNCR), Lyell Immunopharma (LYEL), Xenon Pharmaceuticals (XENE), Emergent BioSolutions (EBS), Dynavax Technologies (DVAX), Supernus Pharmaceuticals (SUPN), Travere Therapeutics (TVTX), BELLUS Health (BLUSF), Axsome Therapeutics (AXSM) and Ligand Pharmaceuticals (LGND).
View all of MRSN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS).

(MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Mersana Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.15%), Bellevue Group AG (4.08%), Rock Springs Capital Management LP (3.87%), Vanguard Group Inc. (3.54%), Artal Group S.A. (2.64%) and Candriam Luxembourg S.C.A. (1.90%). Company insiders that own Mersana Therapeutics stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Eva M Jack, Lawrence M Alleva, Lawrence M Alleva, Scott D Sandell and Timothy B Lowinger.
View institutional ownership trends for Mersana Therapeutics.

MRSN stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, State Street Corp, Citigroup Inc., Bellevue Group AG, Candriam Luxembourg S.C.A., Vanguard Group Inc., UBS Group AG, and Allianz Asset Management GmbH. Company insiders that have sold Mersana Therapeutics company stock in the last two years include Alejandra Carvajal, Anna Protopapas, Arvin Yang, Ashish Mandelia, Eva M Jack, and Timothy B Lowinger.
View insider buying and selling activity for Mersana Therapeutics or view top insider-selling stocks.

MRSN stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Artal Group S.A., Decheng Capital Management III Cayman LLC, Renaissance Technologies LLC, Federated Hermes Inc., Rock Springs Capital Management LP, Goldman Sachs Group Inc., and Pinz Capital Management LP. Company insiders that have bought Mersana Therapeutics stock in the last two years include Andrew A F Hack, and Lawrence M Alleva.
View insider buying and selling activity for Mersana Therapeutics or or view top insider-buying stocks.

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRSN stock can currently be purchased for approximately $4.63.

Mersana Therapeutics (NASDAQ:MRSN) has a market capitalization of $449.07 million and generates $40 thousand in revenue each year. The company earns $-170.06 million in net income (profit) each year or ($2.490010) on an earnings per share basis.

Mersana Therapeutics employs 169 workers across the globe.

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for Mersana Therapeutics is www.mersana.com. The company can be reached via phone at (617) 498-0020 or via email at [email protected].